Comparison of Efficacy and Safety of Left Atrial Appendage Occlusion in Patients Aged <75 to ≥75 Years

Published:October 28, 2015DOI:
      Left atrial appendage occlusion (LAAO) is emerging as a promising alternative to oral anticoagulation. Because aged patients present a greater risk of not only cardioembolic events but also major bleeding, LAAO might represent a valid alternative as this would allow oral anticoagulation cessation while keeping cardioembolic protection. The objective of the study was to explore the safety and efficacy of LAAO in elderly patients. Data from the AMPLATZER Cardiac Plug multicenter registry were analyzed. The cohort was categorized in 2 groups (<75 vs ≥75 years). A total of 1,053 subjects were included in the registry. Of them, 219 were excluded because of combined procedures. As a result, 828 subjects were included (54.6% ≥75 years). Procedural success was high and similar in both groups (97.3%). Acute procedural major adverse events were not statistically different among groups (3.2% in <75 years vs 5.1%; p = 0.17) although stratified analysis showed a higher incidence of cardiac tamponade in elderly patients (0.5% vs 2.2%; p = 0.04). With a median follow-up of 16.8 months, no significant differences in stroke/TIA (1.9% vs 2.3%; p = 0.89) and major bleeding (1.7% vs 2.6%; p = 0.54) were observed. In conclusion, LAAO was associated with similar procedural success in patients aged <75 and ≥75 years although older patients had a higher incidence of cardiac tamponade. At follow-up, stroke and major bleeding rates were similar among groups.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lip G.Y.
        • Frison L.
        • Halperin J.L.
        • Lane D.A.
        Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the has-bled (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score.
        J Am Coll Cardiol. 2011; 57: 173-180
        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation.
        Chest. 2010; 137: 263-272
        • Tzikas A.
        • Shakir S.
        • Gafoor S.
        • Omran H.
        • Berti S.
        • Santoro G.
        • Kefer J.
        • Landmesser U.
        • Nielsen-Kudsk J.E.
        • Cruz-Gonzalez I.
        • Sievert H.
        • Tichelbacker T.
        • Kanagaratnam P.
        • Nietlispach F.
        • Aminian A.
        • Kasch F.
        • Freixa X.
        • Danna P.
        • Rezzagh M.
        • Vermeersch P.
        • Stock F.
        • Stolcova M.
        • Costa M.
        • Ibrahim R.
        • Schillinger W.
        • Meier B.
        • Park J.W.
        Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the Amplatzer cardiac plug.
        EuroIntervention. 2015; 10 (Epub ahead of print)
        • Park J.W.
        • Bethencourt A.
        • Sievert H.
        • Santoro G.
        • Meier B.
        • Walsh K.
        • Lopez-Minquez J.R.
        • Meerkin D.
        • Valdes M.
        • Ormerod O.
        • Leithauser B.
        Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience.
        Catheter Cardiovasc Interv. 2011; 77: 700-706
        • Holmes Jr., D.R.
        • Kar S.
        • Price M.J.
        • Whisenant B.
        • Sievert H.
        • Doshi S.K.
        • Huber K.
        • Reddy V.Y.
        Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the prevail trial.
        J Am Coll Cardiol. 2014; 64: 1-12
        • Kappetein A.P.
        • Head S.J.
        • Genereux P.
        • Piazza N.
        • van Mieghem N.M.
        • Blackstone E.H.
        • Brott T.G.
        • Cohen D.J.
        • Cutlip D.E.
        • van Es G.A.
        • Hahn R.T.
        • Kirtane A.J.
        • Krucoff M.W.
        • Kodali S.
        • Mack M.J.
        • Mehran R.
        • Rodes-Cabau J.
        • Vranckx P.
        • Webb J.G.
        • Windecker S.
        • Serruys P.W.
        • Leon M.B.
        Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 Consensus Document.
        J Am Coll Cardiol. 2012; 60: 1438-1454
        • Urena M.
        • Rodes-Cabau J.
        • Freixa X.
        • Saw J.
        • Webb J.G.
        • Freeman M.
        • Horlick E.
        • Osten M.
        • Chan A.
        • Marquis J.F.
        • Champagne J.
        • Ibrahim R.
        Percutaneous left atrial appendage closure with the Amplatzer cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy.
        J Am Coll Cardiol. 2013; 62: 96-102
        • Lam Y.Y.
        • Yip G.W.
        • Yu C.M.
        • Chan W.W.
        • Cheng B.C.
        • Yan B.P.
        • Clugston R.
        • Yong G.
        • Gattorna T.
        • Paul V.
        Left atrial appendage closure with Amplatzer cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience.
        Catheter Cardiovasc Interv. 2012; 79: 794-800
        • Lopez-Minguez J.R.
        • Eldoayen-Gragera J.
        • Gonzalez-Fernandez R.
        • Fernandez-Vegas C.
        • Fuentes-Canamero M.E.
        • Millan-Nunez V.
        • Nogales-Asensio J.M.
        • Martinez-Naharro A.
        • Sanchez-Giralt S.
        • Doblado-Calatrava M.
        • Merchan-Herrera A.
        Immediate and one-year results in 35 consecutive patients after closure of left atrial appendage with the Amplatzer cardiac plug.
        Rev Esp Cardiol. 2013; 66: 90-97
        • Holmes D.R.
        • Reddy V.Y.
        • Turi Z.G.
        • Doshi S.K.
        • Sievert H.
        • Buchbinder M.
        • Mullin C.M.
        • Sick P.
        Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.
        Lancet. 2009; 374: 534-542
        • Reddy V.Y.
        • Sievert H.
        • Halperin J.
        • Doshi S.K.
        • Buchbinder M.
        • Neuzil P.
        • Huber K.
        • Whisenant B.
        • Kar S.
        • Swarup V.
        • Gordon N.
        • Holmes D.
        • PROTECT AF Steering Committee and Investigators
        Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.
        JAMA. 2014; 312: 1988-1998
        • Freixa X.
        • Tzikas A.
        • Sobrino A.
        • Chan J.
        • Basmadjian A.J.
        • Ibrahim R.
        Left atrial appendage closure with the Amplatzer cardiac plug: impact of shape and device sizing on follow-up leaks.
        Int J Cardiol. 2013; 168: 1023-1027